1. Introduction {#sec1}
===============

Metabolic syndrome (MetS) is characterized by a cluster of metabolic disorders, including insulin resistance (IR), hyperglycemia, dyslipidemia, central obesity, and hypertension. These disorders are important risk factors of type 2 diabetes mellitus (T2DM), cardiovascular diseases, and all-cause mortality among adults and children \[[@B1], [@B2]\]. With the worldwide spread of obesity and T2DM, MetS is increasingly being seen as an important public health problem. Overall prevalence of MetS ranges from 21.9% to 49.4% in the general populations of the United States, Europe, and Asia (Thailand, Mainland China, and Hong Kong) \[[@B3]\]. Although IR is considered to be a key factor in the disease, the precise pathogenic mechanism of MetS is not clear. No specific or effective prevention and therapeutic strategies are available for MetS. Thus, it is imperative to identify novel biomarkers to identify MetS.

Adipose tissue is an active endocrine organ secreting a host of bioactive adipokines, including adiponectin and leptin. Adipokines modulate glucose and lipid metabolism, inflammation, and insulin sensitivity and, thus, might be involved in the pathogeneses of IR, diabetes, and MetS \[[@B4]--[@B6]\]. Neuregulin 4 (Nrg4) is a secreted water-soluble protein that has been found in the circulation. Nrg4 is expressed in multiple organs, with the highest expression levels in brown adipose tissue \[[@B7], [@B8]\]. A member of the epidermal growth factor (EGF) family of extracellular ligands, Nrg4 binds to and activates receptor tyrosine kinases ErbB3 and ErbB4 and acts as an autocrine, paracrine, or endocrine signal by releasing the EGF-like domain after photolytic cleavage \[[@B6]--[@B12]\]. Nrg4 has many biological functions, including the inhibition of apoptosis and inflammation and the promotion of neurite outgrowth \[[@B11], [@B13]--[@B17]\]. Rosell and Kaforou \[[@B17]\] showed that Nrg4 is upregulated in cold-induced beige/brite cells and highly expressed during brown adipocyte differentiation. Nrg4 mRNA expression was downregulated in the adipose tissues of several obese mouse models and negatively correlated with the percentage of body fat mass and liver fat content in humans \[[@B6], [@B8], [@B18]\]. These observations suggest that Nrg4 insufficiency may be a common feature of obesity. Furthermore, Nrg4-deficient mice fed a high-fat diet exhibited significant increases in body weight (BW), plasma triacylglyceride and fasting blood glucose levels, and worsening of IR and fatty liver. Nrg4-overexpressing mice displayed the opposite results in liver and adipose tissues \[[@B7], [@B8]\]. These results demonstrate that Nrg4 may play a crucial role in the regulation of insulin sensitivity, energy balance, and glucose and lipid metabolism.

Decreased Nrg4 levels may lead to the development of IR, T2DM, and MetS. A recent study demonstrated that Nrg4 mRNA levels in subcutaneous and visceral adipose tissues were significantly lower in patients with impaired glucose tolerance or T2DM than in normal individuals \[[@B8]\]. These findings suggest that Nrg4 may work as a novel adipokine protecting metabolic homeostasis. However, two recent clinical studies found that serum Nrg4 levels were significantly higher in T2DM patients than in healthy controls and were positively correlated with waist circumference (WC), fasting plasma glucose (FPG) and triglyceride (TG) concentrations, blood pressure, and IR \[[@B19], [@B20]\]. The discrepant findings might be due to differences in study design and methodology.

Recently, Dai et al. \[[@B5]\] indicated that patients with nonalcoholic fatty liver disease (NAFLD) had lower serum levels of Nrg4 than non-NAFLD controls. Decreased serum Nrg4 level was an independent risk factor of NAFLD, which currently is considered to be the hepatic manifestation of IR and MetS \[[@B5]\]. These findings strongly suggest that decreased Nrg4 may contribute to the pathogenesis of MetS. To our knowledge, only one cross-sectional study has investigated the relationship between Nrg4 and MetS in obese adults, showing decreased serum Nrg4 levels in MetS subjects with obesity \[[@B6]\]. No study has analyzed the association between plasma Nrg4 levels and risk of MetS in normal weight, overweight, or obese patients with T2DM. Thus, the purpose of this study was to evaluate the determinants and associations of plasma Nrg4 concentration with MetS characteristics, as defined by the Chinese Medical Association/Chinese Diabetes Society (CDS) diagnostic criteria, in newly diagnosed T2DM (nT2DM) patients.

2. Materials and Methods {#sec2}
========================

2.1. Study Design and Subjects {#sec2.1}
------------------------------

A total of 311 patients with nT2DM were recruited to the study. Diagnosis of T2DM was made on the basis of oral glucose tolerance tests (OGTTs) and 1998 WHO diagnostic criteria. Subjects with nT2DM were not treated with hypoglycemic agents or insulin. All participants completed a standardized questionnaire regarding their medical history and lifestyle factors (smoking and alcohol) and underwent a comprehensive health examination according to standard procedures. Exclusion criteria were as follows: patients with (1) type 1 diabetes mellitus or other endocrine disorder, (2) acute complications of T2DM, gall bladder, or biliary tract disease, viral hepatitis, alcoholic liver disease, drug-induced liver disease, autoimmune hepatitis, liver and renal dysfunction, acute or chronic inflammatory disease, pregnancy, or cardiovascular or cerebral vascular disease, (3) history of use of lipid-lowering and antihypertensive drugs, and (4) total parenteral nutrition, smoking habit, or alcohol consumption. Hypertension without antihypertensive drug treatment was not an exclusion criterion. All nT2DM patients were categorized into quartiles based on their plasma Nrg4 level: quartile 1, Nrg4 \< 1.97 ng/ml; quartile 2, 1.97 ng/ml ≤ Nrg4 \< 2.80 ng/ml; quartile 3, 2.80 ng/ml ≤ Nrg4 ≤ 4.10 ng/ml; quartile 4, Nrg4 \> 4.10 ng/ml. The study protocol followed the ethical guidelines of the 1964 Declaration of Helsinki and was approved by the human research ethics committee of the Affiliated Hospital of Southwest Medical University. Written informed consent was obtained from all patients.

2.2. Definition of MetS {#sec2.2}
-----------------------

MetS was defined by the CDS criteria \[[@B21]\]. For a diagnosis of MetS, participants had to meet three or more of the following criteria: (1) BW in the overweight or obese range, defined as a body mass index (BMI) ≥ 25.0 kg/m^2^; (2) hyperglycemia, defined as FPG ≥ 6.1 mmol/l and/or 2 h plasma glucose (2hPG) ≥ 7.8 mmol/l, or previously diagnosed T2DM and receiving treatment; (3) hypertension, defined as systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥ 140/90 mmHg, or previously diagnosed hypertension and receiving treatment; and (4) dyslipidemia, defined as TG ≥ 1.7 mmol/l and/or high-density lipoprotein cholesterol (HDL-C) \< 0.9 mmol/l (men) or \<1.0 mmol/l (women). Patients with nT2DM were considered to have MetS if they had two or more of the above factors except nT2DM.

2.3. Anthropometric and Biochemical Measurements {#sec2.3}
------------------------------------------------

Anthropometric measurements were performed in all participants before breakfast. BW (kg), height (m), BMI, SBP, and DBP were measured by standard methods, as described previously \[[@B22]\]. Body fat percentage (BF%) was calculated using the following equation \[[@B23]\]: BF% = 1.20 × BMI − 10.8 × sex (male = 1, female = 2) + 0.23 × age (year) − 5.4.

Blood samples were collected from participants in the morning, either after an overnight fast or 2 h after beginning the 75 g OGTT. Plasma samples were collected by centrifugation at 4°C and stored at −80°C until analytical processing. FPG, 2hPG, and glycated hemoglobin A1C (HbA1c) levels were measured by the glucose oxidase method and anion-exchange HPLC, respectively. Total cholesterol (TC), TG, HDL-C, low-density lipoprotein cholesterol (LDL-C), apolipoprotein A (apoA), and apolipoprotein B (apoB) levels were analyzed enzymatically by using a 7060 full-automatic biochemical analyzer (Hitachi, Tokyo, Japan). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), and alkaline phosphatase (ALP) levels were also analyzed. White blood cell (WBC), neutrophil, and lymphocyte counts were determined by using an automated blood cell counter (Mindray BC-6800, Shenzhen, China), according to the manufacturer\'s instructions. The neutrophil to lymphocyte ratio (NLR) was calculated as the simple ratio between the absolute neutrophil and lymphocyte counts. High-sensitivity C-reactive protein (hs-CRP) levels were measured by latex-enhanced immunoturbidimetric assay. Fasting plasma insulin (FIns) concentrations were measured with an electrochemiluminescence immunoassay (Roche Elecsys Insulin Test, Roche Diagnostics, Mannheim, Germany). The apoB to apoA ratio (apoB/apoA) was calculated as the simple ratio between apoB and apoA. The triglyceride glucose (TyG) index was calculated as the natural logarithm of \[TG (mg/dl) × FPG (mg/dl)/2\] \[[@B24]\]. Homeostasis model assessment of insulin resistance (HOMA-IR) and homeostasis model assessment of *β*-cell insulin secretion (HOMA-IS) were calculated from FIns and FPG levels by the following formulas \[[@B4]\]: HOMA-IR = FIns (*μ*U/ml) × FPG (mmol/l)/22.5 and HOMA-IS = \[20 × FIns (*μ*U/ml)\]/\[FPG (mmol/l) − 3.5\].

2.4. Plasma Nrg4 Measurement {#sec2.4}
----------------------------

Plasma Nrg4 concentrations were determined with an enzyme-linked immunosorbent assay (ELISA) (Aviscera Biosciences, Santa Clara, CA), following the manufacturer\'s protocol. This assay has been shown to be highly sensitive to human Nrg4, with a sensitivity of 0.125--0.25 ng/ml. The linear range of the standard was 0.25--16.0 ng/ml. Intra- and inter-assay variations were both less than 10%.

2.5. Statistical Analysis {#sec2.5}
-------------------------

All analyses were performed with the Statistical Package for Social Sciences version 20.0 (SPSS, Chicago, IL). All data distributions were analyzed for normality by the Kolmogorov--Smirnov test. Data are expressed as the mean ± standard deviation (SD) for continuous variables or percentage (%) for categorical variables, unless otherwise specified. Two groups were compared by chi-square (*χ*^2^) tests for categorical variables, Student\'s *t*-test for normally distributed continuous variables, or Mann--Whitney *U* tests for nonparametric distributed continuous variables. More than two groups were compared by one-way analysis of variance (ANOVA) followed by the post hoc least significant difference test for normally distributed continuous variables and Kruskal--Wallis test followed by adjustment for multiple pairwise comparisons for nonparametric distributed covariates. Spearman\'s correlation coefficients were used to describe associations between plasma Nrg4 concentration and other variables. The partial correlation coefficient was used for sex- and age-adjusted data.

Multiple linear regression was performed to identify variables that were independently associated with plasma Nrg4 concentration. Logistic regression analysis was performed to ascertain the association of Nrg4 concentration with the presence of MetS. In logistic regression, we analyzed all potential confounding variables. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. All reported *P* values were two-sided, and a *P* value of \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Clinical and Biochemical Characteristics of nT2DM Patients with or without MetS {#sec3.1}
------------------------------------------------------------------------------------

[Table 1](#tab1){ref-type="table"} summarizes the anthropometric and biochemical parameters of the 311 nT2DM patients enrolled in the cross-sectional study. Compared to nT2DM patients without MetS, nT2DM patients with MetS had higher levels of BMI, BF%, SBP, DBP, TC, TG, apoB, FPG, 2hPG, ALT, GGT, WBC count, hs-CRP, FIns, HOMA-IR, apoB/apoA, and TyG index (*P* \< 0.001 or *P* \< 0.01 or *P* \< 0.05) and lower levels of HDL-C, apoA, and lymphocyte count (*P* \< 0.001 or *P* \< 0.05). Age, LDL-C, HbA1c, ALP, NLR, neutrophil count, and HOMA-IS did not significantly differ between the groups.

3.2. Plasma Nrg4 Levels Depending on MetS Components in nT2DM Patients {#sec3.2}
----------------------------------------------------------------------

Plasma Nrg4 levels were lower in nT2DM patients with MetS than in those without MetS (*P* = 0.001; [Figure 1(a)](#fig1){ref-type="fig"}). Furthermore, plasma Nrg4 levels were significantly lower in nT2DM patients with elevated TG levels (*P* \< 0.01; [Figure 1(c)](#fig1){ref-type="fig"}), decreased HDL-C levels (*P* \< 0.05; [Figure 1(d)](#fig1){ref-type="fig"}), and overweight or obese patients (*P* \< 0.01; [Figure 1(e)](#fig1){ref-type="fig"}) compared to their controls. Plasma Nrg4 levels decreased in a stepwise fashion as the number of MetS components increased (*P* for trend \< 0.01; [Figure 1(f)](#fig1){ref-type="fig"}). Subjects with four or five components of MetS had lower plasma Nrg4 levels than those with only one component (*P* \< 0.01). However, there was no significant difference in plasma Nrg4 levels in the context of hypertension (*P* \> 0.05; [Figure 1(b)](#fig1){ref-type="fig"}).

3.3. Clinical and Biochemical Characteristics in nT2DM Patients according to Plasma Nrg4 Quartile {#sec3.3}
-------------------------------------------------------------------------------------------------

[Table 2](#tab2){ref-type="table"} presents the clinical and biochemical characteristics distinguished by quartile of plasma Nrg4 concentration. TG, HDL-C, apoA, GGT, hs-CRP, and Nrg4 concentrations and WBC count were significantly different between patients in different plasma Nrg4 quartiles (*P* \< 0.001 or *P* \< 0.01 or *P* \< 0.05). Compared to subjects in the lowest quartile of plasma Nrg4 concentration, patients in the highest quartile had lower levels of BMI, TG, GGT, WBC count, and hs-CRP (*P* \< 0.01 or *P* \< 0.05) and higher levels of plasma Nrg4, HDL-C, and apoA (*P* \< 0.001 or *P* \< 0.01 or *P* \< 0.05). Prevalence of MetS was markedly lower in subjects in the highest plasma Nrg4 quartile than in subjects in the lowest quartile (*P* \< 0.01). However, prevalence of overweight or obesity, hypertension, elevated TG levels, and decreased HDL-C levels showed no significant differences across quartiles of plasma Nrg4 concentration.

3.4. Linear Regression Analyses of Variables Associated with Plasma Nrg4 Levels in All nT2DM Patients {#sec3.4}
-----------------------------------------------------------------------------------------------------

We investigated the relationship between plasma Nrg4 concentration and the other parameters. Plasma Nrg4 levels were correlated positively with HDL-C and apoA levels but negatively with TG, hs-CRP, and GGT levels and WBC and neutrophil counts (*P* ≤ 0.001 or *P* \< 0.01 or *P* \< 0.05). All of these correlations remained statistically significant after adjusting for sex and age (all *P* \< 0.05). We performed multiple stepwise regressions to determine which variables were independently associated with plasma Nrg4 concentration. Only hs-CRP level, WBC count, and HDL-C level were independently related to plasma Nrg4 concentration (*P* = 0.001 or *P* \< 0.05), with a multiple regression equation of *Y*~Nrg4~ = 3.449 − 0.194*X*~hs-CRP~ − 0.131*X*~WBC~ + 0.646*X*~HDL-C~ ([Table 3](#tab3){ref-type="table"}).

Multivariable-adjusted ORs for the association of plasma Nrg4 concentration with increased presence of MetS are shown in [Table 4](#tab4){ref-type="table"}. Risk of presence of MetS decreased by 15% per 1 SD increase in plasma Nrg4 levels. The OR of MetS as predicted by Nrg4 concentration in the presence of all potential confounding variables was 0.560 (95% CI: 0.374--0.837; *P* \< 0.01), indicating that there was a 44% decrease in the odds of having MetS for each 1 ng/ml increase in Nrg4 levels.

4. Discussion {#sec4}
=============

Plasma concentrations of Nrg4, a novel adipokine expressed in adipose tissues (especially brown adipose tissue), may be associated with obesity, IR, T2DM, lipid metabolism, inflammation, and atherosclerosis \[[@B6], [@B8], [@B9], [@B15]\]. When fed a high-fat diet, mice overexpressing Nrg4 specifically in the liver and adipose tissues gained significantly less weight than control mice and exhibited improvements in glucose tolerance, lipid metabolism, and insulin sensitivity, and decreased hepatic steatosis \[[@B8], [@B18]\]. In humans, several studies found that Nrg4 mRNA levels were significantly lower in the subcutaneous and visceral adipose tissues of individuals with impaired glucose tolerance and T2DM. Moreover, Nrg4 mRNA or circulating Nrg4 levels were negatively related to the presence of MetS components \[[@B6], [@B8]\]. Taken together, these previous observations suggest that plasma Nrg4 concentration might be a useful biomarker of obesity-related metabolic and cardiovascular disorders.

In this report, we describe the first clinical study in a Chinese nT2DM population. Consistent with previous findings \[[@B6]\], we observed that plasma Nrg4 levels were significantly lower in nT2DM patients with MetS than in nT2DM patients without MetS. Plasma Nrg4 levels progressively decreased as the number of components of MetS increased. Prevalence of MetS was significantly lower in subjects in the highest quartile of plasma Nrg4 concentration than in those in the lowest quartile. Plasma Nrg4 levels were positively correlated with a favorable lipid profile (high levels of HDL-C and apoA) and negatively correlated with an unfavorable metabolic profile (high levels of TG). Most importantly, we found that plasma Nrg4 concentration was independently associated with MetS, even after adjusting for all potential confounders. Collectively, these data demonstrate that Nrg4 is an independent protective factor for MetS and that decreased Nrg4 concentration may play an important role in the pathophysiology of MetS. However, the underlying mechanism remains unclear.

IR has been considered to be a key factor for development of MetS. HOMA-IR is a validated and widely used method to evaluate IR from FPG and FIns in large-scale and epidemiological studies \[[@B24], [@B25]\]. The TyG index was shown to be more sensitive and specific for IR than the euglycemic-hyperinsulinemic clamp \[[@B25]\]. The apoB/apoA ratio was significantly associated with IR in nondiabetic subjects in the United States, independent of traditional risk factors, MetS components, and inflammatory risk factors \[[@B26]\]. As expected, we found that compared to nT2DM patients without MetS, those with MetS had elevations of indicators of IR (FIns, HOMA-IR, apoB/apoA, and TyG index), suggesting that IR plays an important role in the development of MetS. Unfortunately, we did not find any difference in IR among patients in the four plasma Nrg4 quartiles, nor were plasma Nrg4 concentrations correlated with any index of IR. These data suggest that Nrg4 may not have a direct role in IR. Several previous studies demonstrated that Nrg4 overexpression could attenuate obesity-induced IR in animal models \[[@B7]--[@B9], [@B18]\]. In contrast, two recent clinical studies found that there were no differences in HOMA-IR among obese adults with different quartiles of serum Nrg4 concentration \[[@B9]\] and that circulating Nrg4 concentration was positively correlated with IR \[[@B19]\]. The discrepant findings between our study and those of the previous clinical trials might be due to methodological differences (e.g., in MetS definition, sample size, smoking habit, selected subgroups, and inclusion/exclusion criteria). In the present study, the OR for the association of plasma Nrg4 concentration with increased presence of MetS remained significant even after we adjusted for potential confounders, including all measures of IR. Hence, low plasma Nrg4 concentration seemed to add to the risk of MetS independently of IR, suggesting that plasma Nrg4 may protect against MetS via IR-independent mechanisms.

Accumulating experimental evidence suggests that all of the components of MetS, including IR, T2DM, hypertension, dyslipidemia, and visceral obesity, may increase oxidative stress and reduce antioxidant defenses \[[@B27]\]. Oxidative stress is thought to mediate the development of MetS \[[@B28]\]. GGT, a biomarker of hepatobiliary disease and alcohol consumption/abuse, is the principal enzyme responsible for extracellular catabolism of the antioxidant glutathione \[[@B29]--[@B31]\]. Elevated levels of GGT are involved in oxidative stress, lipid peroxidation, and mitochondrial dysfunction \[[@B31]\], and serum GGT activity changes in response to oxidative stress \[[@B29]\]. GGT levels were correlated positively with a marker of oxidative stress (F2-isoprostanes) and negatively with antioxidant levels \[[@B30]\]. Recent epidemiological and experimental data revealed that elevations in serum GGT concentration were associated with the presence of MetS and its components, even after adjustment for alcohol consumption and established risk factors \[[@B29], [@B31]\]. Consistent with these observations, we found that plasma GGT levels were lower in nT2DM patients with MetS than in those without MetS, suggesting that plasma GGT levels play an important role in the development of MetS. Surprisingly, we also found that plasma GGT levels were significantly different among patients in the four quartiles of plasma Nrg4 concentration, with nT2DM patients in the highest quartile exhibiting significantly lower levels of GGT than patients in the lowest quartile. Thus, there seems to be cross talk between plasma Nrg4 and GGT levels. Plasma Nrg4 levels remained significantly and negatively correlated with GGT after controlling for sex and age in a partial correlation analysis. Slattery et al. \[[@B32]\] recently reported that *Nrg4* gene expression was upregulated among patients with high oxidative balance scores (lower oxidative stress) compared to patients with lower scores. These results suggest that Nrg4 could potentially be used as a biomarker of oxidative stress and that decreased Nrg4 levels are likely a consequence of the augmented oxidative stress in MetS. Further study of this novel relationship between Nrg4 and GGT is warranted.

Chronic low-grade inflammation has been associated strongly with obesity and IR and, therefore, MetS \[[@B33]\]. A sensitive biomarker of low-grade systemic inflammation, hs-CRP is produced and released by the liver under the stimulation of proinflammatory cytokines \[[@B34]\]. Several studies support the concept that hs-CRP is a predictor of cardiovascular disease and T2DM \[[@B33], [@B35]\]. High concentrations of hs-CRP have been associated with MetS and its individual components in different populations \[[@B35]\]. WBC count is a routinely used marker of systemic inflammation that recently was reported to be associated with MetS and its individual components \[[@B36]\]. In nondiabetic individuals, lymphocyte count was associated with insulin sensitivity and adiposity \[[@B37], [@B38]\]. Neutrophil count correlates with hs-CRP concentration better than any other major white cell type \[[@B39]\]. Finally, numerous studies linked elevated levels of WBC subfractions (neutrophil and lymphocyte counts) and NLR to MetS \[[@B38]\]. We found that nT2DM patients with MetS had higher levels of several inflammatory markers (WBC, NLR, and hs-CRP) and lower lymphocyte counts than patients without MetS. These findings confirm the well-known association of these inflammatory markers with MetS in adults. In addition, nT2DM patients in the highest quartile of plasma Nrg4 levels had significantly lower WBC counts and hs-CRP levels than subjects in the lowest quartile. Thus, there seems to be a potential relationship between plasma Nrg4 levels and inflammation. Nrg4 may regulate the expression of proinflammatory cytokines in adipose tissue and influence circulating levels of WBCs and hs-CRP. Partial correlation analysis confirmed that the plasma Nrg4 levels were significantly and negatively correlated with hs-CRP level, WBC count, and neutrophil count after controlling for sex and age. Therefore, Nrg4 may play a key regulatory and anti-inflammatory role in development of MetS. Most importantly, hs-CRP and WBC were independently related to plasma Nrg4 levels. Taken together, these results demonstrate that proinflammatory cytokines may suppress Nrg4 expression in adipocytes. Thus, the reduction of plasma Nrg4 concentration is likely a consequence of augmented proinflammatory cytokine signaling in obesity \[[@B8]\]. Consistent with this hypothesis, recent studies demonstrated the interaction of Nrg4 with inflammation. For example, Bernard et al. \[[@B14]\] showed that Nrg4 expression was decreased in human inflammatory bowel diseases (Crohn disease and ulcerative colitis) and in mouse models of colitis, which may allow for macrophage persistence and ongoing inflammation. Similarly, Feng and Teitelbaum \[[@B40]\] reported reduced levels of Nrg4 in a mouse model of total parenteral nutrition-induced small intestinal inflammation. McElroy et al. \[[@B13]\] found that Nrg4 can protect against experimental necrotizing enterocolitis. Ma et al. \[[@B18]\] observed that Nrg4 overexpression reduced expression of genes encoding macrophage markers and the macrophage chemokine Mcp1 in liver and adipose tissues. Most recently, Schumacher et al. \[[@B15]\] suggested that Nrg4 expression in C57Bl/6 mice was suppressed by active inflammation during experimental colitis and rebounded during the recovery phase. Administration of exogenous Nrg4 reduced colonic macrophage numbers and ameliorated inflammation. Taken together, these previous and our present findings consistently raise the possibility that Nrg4 may have an important anti-inflammatory role through stimulating proinflammatory macrophage apoptosis and reducing gene expression of macrophage markers. The augmentation of inflammation due to Nrg4 downregulation may be important for the development of MetS. Future study is required to confirm our findings.

Obesity and dyslipidemia are the components of MetS that are most often seen in patients with T2DM. Obesity per se is an important risk factor of T2DM development and is associated with low-grade systemic inflammation and dyslipidemia. BMI is commonly used as a standard measurement of overall adiposity in adults \[[@B41]\]. Using both BMI and BF% provided more accurate measurements of the degree of obesity, especially for muscular athletes \[[@B42]\]. Elevated TG and reduced HDL-C levels reflect impaired lipid metabolism and are the main phenotypic features of dyslipidemia in diabetes \[[@B43]\]. Consistent with these findings, we found that compared to nT2DM patients without MetS, patients with MetS had higher levels of parameters of adiposity (BMI and BF%), TC, TG, and apoB, and lower levels of HDL-C and apoA, suggesting that obesity and dyslipidemia play key roles in development of MetS. In addition, patients in the highest quartile of Nrg4 concentration showed significantly lower BMIs and TG levels and significantly higher HDL-C and apoA levels than patients in the lowest quartile. Plasma Nrg4 levels were correlated negatively with TG and positively with HDL-C and apoA levels, even after adjusting for sex and age. These correlations reflect the role of Nrg4 in the modulation of weight and lipid metabolism. Our findings are inconsistent with those of two recent studies \[[@B19], [@B20]\], which showed that serum Nrg4 levels were or were not positively correlated with parameters of adiposity (BMI, WC, hip circumference, and neck circumference) and TG and were negatively correlated with HDL-C levels. The discrepant findings might be due to methodological differences. Meanwhile, Wang et al. \[[@B8]\] reported that Nrg4 mRNA expression was downregulated in the adipose tissues of several mouse models of obesity and inversely correlated with the percentage of body fat mass and liver fat content in humans. Nrg4 overexpression protected mice from diet-induced weight gain and adiposity and inhibited lipogenesis through liver X receptor (LXR) and sterol-regulatory element binding protein 1c (SREBP1c) and its target genes \[[@B8]\]. Similarly, Ma and colleagues \[[@B18]\] demonstrated that Nrg4 overexpression increased the expression of adipose triglyceride lipase (*Atgl*) gene and blocked hepatic lipid storage by inhibiting expression of peroxisome proliferator-activated receptor gamma (PPAR*γ*) and its target genes. Consistent with these findings, we found that plasma Nrg4 levels were significantly lower in patients with overweight or obesity or decreased HDL-C or elevated TG levels compared to their controls. Our multiple stepwise regression analyses showed that HDL-C level was independently correlated with plasma Nrg4 level. However, the physiological mechanisms underlying the relationship between Nrg4 and HDL-C remain obscure.

Our study has some limitations. Firstly, our findings must be interpreted with caution because the cross-sectional study design makes it hard to infer causality between plasma Nrg4 levels and MetS. Large prospective studies are needed to verify this potential causal relationship. Secondly, our findings may not be generalizable to other populations because the study was based on Chinese nT2DM patients at a single center. Further studies are warranted to determine the role of plasma Nrg4 in the development of MetS in other populations. Thirdly, the current gold standard to recognize IR, euglycemic-hyperinsulinemic clamp, is less frequently used and difficult to apply in large studies. As Nrg4 is thought to be related to IR, this study failed to examine the relationship between plasma Nrg4 levels and IR, as measured by HOMA-IR, apoB/apoA, and TyG index. Fourthly, our analyses were based on a single determination of plasma Nrg4 level, which is subject to random measurement error and may have underestimated the strength of the associations. Fifthly, newly diagnosed hypertension subjects were not excluded because of their small numbers. Their inclusion or exclusion would not have materially affected the results. Finally, BMI and BF% were used instead of WC to represent abdominal obesity. Although BMI might not represent fat accumulation accurately, BMI ≥ 25 kg/m^2^ was equivalent to WC = 85.5 cm (a value similar to the Japanese-specific cutoff point for abdominal obesity) as a predictor of the 5-year incidence of diabetes in Japanese--American men \[[@B44]\]. We believe that this CDS MetS criterion would not change the main implications of the present study.

Our study also has several strengths. This study included a relatively large number of patients. Furthermore, we tentatively defined MetS using CDS criteria appropriate for the Chinese population. Most importantly, our study is, to our knowledge, the first to evaluate the association between plasma Nrg4 level and MetS in Chinese nT2DM patients.

5. Conclusion {#sec5}
=============

Our study examines a possible mechanistic association between the plasma Nrg4 level and MetS in nT2DM subjects. Plasma Nrg4 level could be a potential biomarker for the development of MetS. Further prospective studies are required to confirm the contribution of Nrg4 to the development of MetS. If this correlation were to be confirmed, increasing the levels of circulating Nrg4 might be crucial for the prevention or management of MetS and its related diseases.
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###### 

Clinical and biochemical characteristics of nT2DM patients with and without MetS.

  Covariate               Without MetS (*n* = 133)   With MetS (*n* = 178)   *P* value
  ----------------------- -------------------------- ----------------------- -----------
  Male/female             65/68                      83/95                   0.696
  Age (years)             53.21 ± 10.36              54.06 ± 9.86            0.464
  BMI (kg/m^2^)           22.71 ± 2.43               26.96 ± 3.24            \<0.001
  BF% (%)                 26.10 ± 4.87               31.06 ± 4.61            \<0.001
  SBP (mmHg)              121.84 ± 9.90              129.79 ± 16.34          \<0.001
  DBP (mmHg)              71.99 ± 8.62               76.42 ± 9.48            \<0.001
  FPG (mmol/l)            10.11 ± 3.76               11.00 ± 3.59            0.036
  2hPG (mmol/l)           17.38 ± 8.32               18.57 ± 5.64            0.017
  HbA1c (%)               9.37 ± 2.83                9.38 ± 1.98             0.957
  TC (mmol/l)             4.29 ± 0.93                4.77 ± 1.62             0.040
  TG (mmol/l)             1.30 ± 0.62                2.85 ± 2.26             \<0.001
  HDL-C (mmol/l)          1.31 ± 0.29                1.00 ± 0.34             \<0.001
  LDL-C (mmol/l)          2.63 ± 0.80                2.78 ± 1.02             0.147
  apoA (g/l)              1.53 ± 0.33                1.36 ± 0.26             \<0.001
  apoB (g/l)              0.84 ± 0.21                0.97 ± 0.29             \<0.001
  ALT (U/l)               22.03 ± 13.45              25.26 ± 13.87           0.006
  AST (U/l)               21.72 ± 13.05              22.30 ± 10.53           0.139
  GGT (U/l)               35.81 ± 6.21               40.75 ± 2.81            \<0.001
  ALP (U/l)               88.94 ± 44.47              83.06 ± 38.15           0.389
  WBC (×10^9^/l)          6.52 ± 1.77                7.22 ± 2.56             0.004
  Neutrophil (×10^9^/l)   4.45 ± 1.59                4.91 ± 2.42             0.148
  Lymphocyte (×10^9^/l)   1.51 ± 0.55                1.68 ± 0.58             0.010
  NLR                     3.51 ± 0.25                3.58 ± 0.29             0.317
  hs-CRP (mg/l)           5.98 ± 1.33                6.34 ± 0.96             0.007
  FIns (*μ*U/ml)          8.45 ± 4.68                11.04 ± 7.26            0.002
  HOMA-IR                 3.80 ± 2.61                5.30 ± 3.92             \<0.001
  HOMA-IS                 39.98 ± 37.33              39.63 ± 41.68           0.619
  TyG index               4.94 ± 0.30                5.29 ± 0.47             \<0.001
  apoB/apoA               0.57 ± 0.19                0.73 ± 0.23             \<0.001

BMI: body mass index; BF%: body fat percentage; SBP: systolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; 2hPG: 2 h plasma glucose; HbA1c: glycated hemoglobin A1c; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; apoA: apolipoprotein A; apoB: apolipoprotein B; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltransferase; ALP: alkaline phosphatase; WBC: white blood cell; NLR: neutrophil to lymphocyte ratio; hs-CRP: high-sensitivity C-reactive protein; FIns: fasting plasma insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-IS: homeostasis model assessment of *β*-cell insulin secretion; apoB/apoA: apolipoprotein A/apolipoprotein B; TyG: triglyceride glucose.

###### 

Clinical and biochemical characteristics by quartile of plasma Nrg4 concentration in all nT2DM patients.

  Covariate                        Quartile 1       Quartile 2         Quartile 3         Quartile 4         *P* value
  -------------------------------- ---------------- ------------------ ------------------ ------------------ -----------
  Nrg4 (ng/ml)                     1.49 ± 0.31      2.30 ± 0.24^∗∗∗^   3.38 ± 0.38^∗∗∗^   5.99 ± 1.69^∗∗∗^   \<0.001
  Male/female                      41/36            37/41              33/46              37/40              0.560
  Age (years)                      53.45 ± 9.61     52.56 ± 10.75      52.85 ± 10.52      55.95 ± 9.11       0.142
  BMI (kg/m^2^)                    26.09 ± 3.73     24.89 ± 3.70^∗^    24.98 ± 3.59       24.61 ± 3.23^∗^    0.054
  BF% (%)                          29.91 ± 5.39     28.61 ± 5.92       28.57 ± 5.11       28.68 ± 4.76       0.333
  SBP (mmHg)                       126.03 ± 15.36   127.37 ± 14.88     125.66 ± 14.56     126.52 ± 13.25     0.894
  DBP (mmHg)                       75.09 ± 10.89    75.09 ± 9.01       73.85 ± 8.87       74.08 ± 8.64       0.766
  FPG (mmol/l)                     10.48 ± 3.85     11.18 ± 3.95       10.38 ± 3.57       10.44 ± 3.37       0.496
  2hPG (mmol/l)                    18.29 ± 8.37     18.81 ± 7.40       17.41 ± 5.98       17.75 ± 5.69       0.605
  HbA1c (%)                        8.90 ± 2.24      9.67 ± 2.53        9.24 ± 2.13        9.61 ± 2.56        0.244
  TC (mmol/l)                      4.51 ± 1.37      4.43 ± 1.29        4.81 ± 1.76        4.52 ± 1.01        0.503
  TG (mmol/l)                      2.56 ± 2.48      2.47 ± 2.07        1.95 ± 1.49        1.76 ± 1.27^∗^     0.006
  HDL-C (mmol/l)                   1.02 ± 0.31      1.12 ± 0.38        1.17 ± 0.36^∗^     1.22 ± 0.34^∗∗^    0.005
  LDL-C (mmol/l)                   2.70 ± 0.86      2.50 ± 0.88        2.89 ± 1.08        1.22 ± 0.34        0.124
  apoA (g/l)                       1.36 ± 0.28      1.38 ± 0.25        1.48 ± 0.34        1.51 ± 0.31        0.020
  apoB (g/l)                       0.92 ± 0.26      0.91 ± 0.27        0.93 ± 0.31        0.91 ± 0.24        0.979
  ALT (U/l)                        24.50 ± 16.06    24.54 ± 13.07      24.35 ± 13.93      22.09 ± 11.77      0.551
  AST (U/l)                        23.26 ± 14.92    21.42 ± 8.91       22.93 ± 12.61      20.60 ± 9.16       0.555
  GGT (U/l)                        42.82 ± 9.55     45.13 ± 5.83       39.72 ± 4.55       26.80 ± 3.12^∗^    0.013
  ALP (U/l)                        86.55 ± 44.65    85.85 ± 47.29      88.42 ± 38.42      81.43 ± 32.54      0.563
  WBC (×10^9^/l)                   7.46 ± 2.17      7.19 ± 3.07        6.47 ± 1.74^∗∗^    6.59 ± 1.78^∗^     0.018
  Neutrophil (×10^9^/l)            5.04 ± 1.96      5.03 ± 2.98        4.30 ± 1.60        4.50 ± 1.54        0.065
  Lymphocyte (×10^9^/l)            1.69 ± 0.61      1.53 ± 0.57        1.65 ± 0.53        1.55 ± 0.57        0.240
  NLR                              3.81 ± 0.44      4.04 ± 0.57        3.06 ± 0.23        3.29 ± 0.20        0.096
  hs-CRP (mg/l)                    12.64 ± 1.98     6.68 ± 2.07^∗∗^    3.55 ± 0.88^∗∗∗^   1.94 ± 0.54^∗∗∗^   \<0.001
  FIns (*μ*U/ml)                   9.75 ± 5.69      11.46 ± 7.94       8.89 ± 5.83        9.64 ± 5.74        0.175
  HOMA-IR                          4.44 ± 3.06      5.71 ± 4.54        4.15 ± 3.24        4.33 ± 2.68        0.113
  HOMA-IS                          42.64 ± 5.50     38.50 ± 3.89       34.47 ± 4.27       38.49 ± 4.32       0.755
  TyG index                        5.17 ± 0.47      5.21 ± 0.43        5.12 ± 0.48        5.05 ± 0.38        0.124
  apoB/apoA                        0.70 ± 0.24      0.68 ± 0.22        0.66 ± 0.24        0.63 ± 0.20        0.273
  MetS, *n* (%)                    55 (71.43)       46 (58.97)         43 (43.04)^∗∗^     34 (44.16)^∗∗^     0.007
  Components of MetS                                                                                         
  Overweight or obesity, *n* (%)   43 (55.84)       35 (44.87)         40 (36.71)         29 (37.66)         0.130
  Hypertension, *n* (%)            16 (20.78)       14 (17.95)         11 (13.92)         11 (14.29)         0.623
  Elevated TG, *n* (%)             41 (53.25)       39 (50)            34 (34.18)         27 (35.06)         0.109
  Decreased HDL-C, *n* (%)         31 (40.26)       24 (30.77)         20 (20.25)         16 (20.78)         0.050

^∗^ *P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001 versus quartile 1 group.

###### 

Linear regression analysis of variables associated with plasma Nrg4 concentration in all nT2DM patients.

  Variable     Simple Estimate   *P* value   Adjusted *P* value^∗^   Multiple Estimate   *P* value
  ------------ ----------------- ----------- ----------------------- ------------------- -----------
  Sex          0.040             0.487                                                   
  Age          0.099             0.081                                                   
  BF%          −0.049            0.392       0.272                                       
  BMI          −0.127            0.025       0.263                                       
  SBP          0.016             0.772       0.674                                       
  DBP          −0.084            0.139       0.685                                       
  TC           0.049             0.386       0.998                                       
  TG           −0.208            \<0.001     0.046                                       
  HDL-C        0.194             0.001       0.016                   0.119               0.035
  LDL-C        0.030             0.600       0.785                                       
  apoA         0.159             0.005       0.028                                       
  apoB         −0.035            0.547       0.750                                       
  apoB/apoA    −0.121            0.034       0.127                                       
  ALT          −0.010            0.864       0.471                                       
  AST          −0.023            0.688       0.534                                       
  GGT          −0.119            0.037       0.049                                       
  ALP          −0.052            0.360       0.333                                       
  WBC          −0.156            0.006       0.012                   −0.131              0.020
  Neutrophil   −0.118            0.037       0.041                                       
  Lymphocyte   −0.066            0.244       0.377                                       
  NLR          −0.043            0.454       0.150                                       
  hs-CRP       −0.447            \<0.001     \<0.001                 −0.194              0.001
  FPG          −0.005            0.935       0.857                                       
  2hPG         −0.046            0.423       0.637                                       
  HbA1c        0.043             0.449       0.103                                       
  TyG index    −0.097            0.087       0.215                                       
  FIns         −0.051            0.366       0.477                                       
  HOMA-IR      −0.039            0.493       0.800                                       
  HOMA-IS      −0.035            0.538       0.637                                       

^∗^Adjusted for sex and age.

###### 

Odds ratios for the presence of MetS according to plasma Nrg4 concentration in all nT2DM patients.

            Increased MetS OR (95% CI)   *P* value
  --------- ---------------------------- -----------
  Model 1   0.85 (0.752--0.961)          0.009
  Model 2   0.833 (0.717--0.967)         0.016
  Model 3   0.750 (0.574--0.980)         0.035
  Model 4   0.741 (0.555--0.990)         0.042
  Model 5   0.683 (0.492--0.947)         0.022
  Model 6   0.560 (0.374--0.837)         0.005

OR: odds ratio; CI: confidence interval. Model 1 unadjusted; model 2 adjusted for sex, age, and parameters of adiposity (BMI and BF%); model 3 adjusted for factors listed in model 2 plus parameters of glycolipid metabolism (SBP, DBP, FPG, 2hPG, HbA1c, TC, TG, HDL-C, LDL-C, apoA, and apoB); model 4 adjusted for factors listed in model 3 plus measures of insulin resistance (apoB/apoA, TyG index, FIns, HOMA-IR, and HOMA-IS); model 5 adjusted for factors listed in model 4 plus markers of inflammation (WBC count, neutrophil count, lymphocyte count, NLR, and hs-CRP); model 6 adjusted for factors listed in model 4 plus biomarkers of liver function (ALT, AST, GGT, and ALP).

[^1]: Academic Editor: Julie Bienertová-Vašků
